Allogeneic stem cell transplantation (alloHSCT) is approved for the treatment of transfusion-dependent thalassemia but remains limited to the use of matched sibling donors. In this multi-centre, phase-4 prospective clinical trial, the authors evaluate the use of alloHSCT with matched unrelated donors and haploidentical relatives.
- Rongrong Liu
- Hongwen Xiao
- Yongrong Lai